Imunon, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Stacy R. Lindborg
- Full Time Employees
- 20
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 997 Lenox Drive Lawrenceville NJ United States of America 08648
- IPO Date
- Mar 1, 1999
- CIK
- 0000749647
- Website
- imunon.com
- Similar Companies
- Business
- Imunon, Inc. is a clinical-stage biotechnology company focused on developing DNA-based immunotherapies and vaccines primarily targeting difficult-to-treat cancers and infectious diseases. The company's main products include IMNN-001, a DNA-based immunotherapy in Phase II clinical development for the localized treatment of advanced ovarian cancer, leveraging interleukin-12 to stimulate immune response; IMNN-101, a COVID-19 booster vaccine candidate; IMNN-102, aimed at treating Lassa virus infections; and IMNN-201, a Trp2 tumor-associated antigen vaccine for melanoma in preclinical stages. Imunon also develops broader non-viral DNA technology platforms, including TheraPlas for protein and cytokine coding in solid tumor treatment and PlaCCine for encoding viral antigens to induce strong immune responses. The company manages the full drug development process in-house, comprising bench discovery, active ingredient manufacture, formulation, testing, and clinical production, enhancing flexibility and control. Founded in 1982 and headquartered in Lawrenceville, New Jersey, Imunon operates primarily in the biotechnology sector within healthcare, focusing on immuno-oncology and infectious disease vaccine markets. A significant recent corporate change includes its rebranding from Celsion Corporation to Imunon, Inc. in September 2022, reflecting a strategic pivot towards DNA-based immunotherapies. In 2024 and 2025, the company advanced its key program IMNN-001 to Phase III clinical trials after successful Phase II results demonstrating an 11.1-month median overall survival improvement in ovarian cancer patients. Imunon completed a $10 million registered direct offering in mid-2024 to strengthen its financial position and has conducted a 15% stock dividend to support shareholder value. The company faces Nasdaq compliance challenges but remains focused on expanding its pipeline and commercial development with ongoing research and preclinical programs, including personalized cancer vaccines based on its IndiPlas platform. Imunon's product pipeline and platform technologies position it in the immunotherapy market addressing oncology and viral diseases, emphasizing localized and personalized treatment approaches with proprietary plasmid DNA delivery systems. Its lead clinical asset IMNN-001 and multiple preclinical candidates underline a robust R&D focus, supported by internal manufacturing and quality control capabilities, enabling a vertically integrated development model within its U.S. operations. The company maintains collaborations and investments to advance its therapeutic modalities while navigating capital markets to fund ongoing clinical trials and operational growth. Overall, Imunon, Inc. integrates innovative DNA plasmid technology with immunology to develop transformative medicines for cancer and infectious diseases, operating out of Lawrenceville with a clear path toward late-stage clinical development and commercial readiness. The company's recent financial maneuvers, trial progressions, and pipeline expansions reflect strategic efforts to establish leadership in its niche biotechnology segment.
Company News
IMUNON to Participate in Upcoming Investor Conferences
IMUNON Converts $1.2 Million of Debt-to-Equity
IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan
Imunon, Inc. (IMNN) Shareholder/Analyst Call Transcript
IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review
IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001
IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress
IMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001
Imunon, Inc. (IMNN) Q2 2026 Earnings Call Transcript
IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer
IMUNON to Present IMNN-001 Data at Inaugural AACR Conference on Drug Discovery and Development
IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer
IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer
Exclusive: Imunon Says Lead Drug Continues To Show Promise in Advanced Ovarian Cancer Patients
IMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification
IMUNON to Present at the Life Sciences Investor Forum on June 25th
IMUNON to Present at the Life Sciences Investor Forum on June 25th
IMUNON Announces Up to $10 Million Cash Financing
Imunon, Inc. (IMNN) Q1 2026 Earnings Call Transcript
IMUNON Reports First Quarter 2026 Financial Results and Provides Business Update